Clinical Trial Update: Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating inhaled bimosiamose for safety and efficacy in patients with moderate to severe COPD has completed. The trial was sponsored by Revota…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Bimosiamose (bimosiamose)

Snippet

Sponsor: Revotar Biopharmaceuticals AG | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED